Physician profile
Robert M Frederickson
NPI 1306955497
$6,760.61
in general payments reported to CMS, 2019-2025
45 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $1,094 · 2021: $1,285 · 2022: $1,384 · 2023: $1,004 · 2024: $625 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $786.00 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $726.64 | 2019-2025 | |
| Abbvie INC. | $678.68 | 2021-2025 | |
| Lilly USA, LLC | $479.51 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $369.80 | 2019-2022 | |
| Gilead Sciences, INC. | $356.48 | 2020-2023 | |
| Amgen INC. | $343.27 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Glaxosmithkline, LLC. | $216.14 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $211.91 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.95 | 2019-2025 | Xifaxan |
| Eisai INC. | $191.06 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $175.65 | 2019-2024 | Belsomra, Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $147.95 | 2022-2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $147.26 | 2019-2024 | Trintellix |
| Dexcom, INC. | $142.06 | 2023-2025 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Frederickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.